Skip to content

Myriad Genetics MYGN Licensing Arrangements

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's licensing arrangements.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's licensing arrangements?
Myriad Genetics (MYGN) reported licensing arrangements of $4.7M in Q1 2026.
How has Myriad Genetics's licensing arrangements changed year-over-year?
Myriad Genetics's licensing arrangements decreased by 21.7% year-over-year, from $6M to $4.7M.
What is the long-term trend for Myriad Genetics's licensing arrangements?
Over 5 years (2020 to 2025), Myriad Genetics's licensing arrangements has grown at a 4.3% compound annual growth rate (CAGR), from $3.8M to $4.7M.